Morphic Therapeutic, a biotechnology company developing oral integrin therapies, has entered into a research and development collaboration with Janssen Biotech to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson & Johnson Innovation facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function.   The companie...